A Chinese Phase IIb trial of the mAb has already started, with Mabwell also hoping to initiate a Phase IIa trial in the US.

Please provide your email address to receive an email when new articles are posted on . Minimum pitch in the morning was significantly higher at exacerbation onset and peak vs. baseline. In the ...

—A new study finds that some patients are proactive (they seek immediate treatment), while others tough it out (wishing to avoid the ‘hassle’ or ‘inconvenience’). What can clinicians do to better ...

Patients with chronic obstructive pulmonary disease (COPD) that is in a state of disease stability (DS) have fewer exacerbations and lower mortality, according to study findings published in Chest.

Most chronic obstructive pulmonary disease (COPD) exacerbations were observed in those not treated with controller medications, but less than half of patients in the study received controller ...

—Theses investigators found an increased risk for both individual and composite cardiovascular events following exacerbations of COPD, with sustained risk after 1 year regardless of severity. Reviewed ...

According to a recent study, patients with an exacerbation of chronic obstructive pulmonary disease (COPD) have greater risks of both subsequent exacerbations and mortality. The odds of subsequent ...

ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patientsGlasmacinal, a novel macrolide, was well tolerated ...

Lower levels of serum sclerostin (SOST) were significantly associated with increased risk of lung exacerbations and hospitalizations in adults with chronic obstructive pulmonary disease (COPD), based ...

Patients with acute COPD exacerbations are seen frequently in the emergency department (ED). Acute exacerbations are associated with significant morbidity, mortality and health care expenditures.